IP Verse

Nalmefene For Reduction Of Alcohol Consumption In Specific Target Populations - EP3345604

The patent EP3345604 was granted to H Lundbeck on Jun 7, 2023. The application was originally filed on Jun 27, 2013 under application number EP17206034A. The patent is currently recorded with a legal status of "Granted And Under Opposition".

EP3345604

H LUNDBECK
Application Number
EP17206034A
Filing Date
Jun 27, 2013
Status
Granted And Under Opposition
May 5, 2023
Grant Date
Jun 7, 2023
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions (2)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

BIOGARANMar 6, 2024CASALONGAADMISSIBLE
ALFRED E TIEFENBACHERMar 1, 2024HAMM & WITTKOPPADMISSIBLE

Patent Citations (7) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication NumberPublication Link
DESCRIPTIONWO2010136039
DESCRIPTIONWO2012059103
OPPOSITIONEP2866808
OPPOSITIONEP3138564
OPPOSITIONWO03015783
OPPOSITIONWO2014001427
SEARCHWO03015783

Non-Patent Literature (NPL) Citations (22) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference TextLink
DESCRIPTION- ANTON et al., J. Clin. Psychopharmacol., (20040000), vol. 24, no. 4, pages 421 - 428-
DESCRIPTION- CHILD; TURCOTTE JG, Surgery and portal hypertension. In: The liver and portal hypertension, Saunders, (19640000), pages 50 - 64-
DESCRIPTION- KARHU-VAARA et al., Alcohol. Clin. Exp. Res., (20070000), vol. 31, no. 7, pages 1179 - 1187-
DESCRIPTION- MASON et al., Arch. Gen. Psychiatry, (19990000), vol. 56, pages 719 - 724-
DESCRIPTION- STAROSTA et al., J. Psychiatr. Pract., (20060000), vol. 12, no. 2, pages 80 - 89-
DESCRIPTION- STEVENS et al., N. Engl. J. Med., (20060000), vol. 354, pages 2473 - 2483-
OPPOSITION- Anonymous, "EMA Assessment report Selincro", EPAR - Public assessment report, European Medicines Agency, (20121213), pages 1 - 73, EPAR - Public assessment report, URL: https://www.ema.europa.eu/en/documents/assessment-report/selincro-epar-public-assessment-report_en.pdf, XP093168724-
OPPOSITION- Anonymous, "Guideline on the development of medicinal products for the treatment of alcohol dependence", European Medicines Agency, (20100218), pages 1 - 17, European Medicines Agency, URL: https://www.ema.europa.eu/en/development-medicinal-products-treatment-alcohol-dependence-scientific-guideline, (20170907), XP055404556-
OPPOSITION- Anonymous, "Selincro 18 mg film-coated tablets, Annex I - III", SUMMARY OF PRODUCT CHARACTERISTICS, European Medicines Agency, (20130225), pages 1 - 34, SUMMARY OF PRODUCT CHARACTERISTICS, URL: https://ec.europa.eu/health/documents/community-register/2018/20181120142711/anx_142711_en.pdf, XP093168677-
OPPOSITION- H. Lundbeck, "Press release ''Nalmefene completes clinical phase III programme - submission of the European Marketing Authorization Application (MAA) is expected by the end of 2011", Lundbeck Corporate Release No 442, (20110615), pages 1 - 4, Lundbeck Corporate Release No 442, URL: https://news.cision.com/h--lundbeck-a-s/r/nalmefene-completes-clinical-phase-iii-programme---submission-of-the-european-marketing-authorization-application--maa--is-expected-by-the-end-of-2011,c2809126, (20170907), XP055404527-
OPPOSITION- Ina Richling, "Reduktion statt Abstinenz: Revival für Nalmefen zur Behandlung Alkoholabhängiger", DEUTSCHE APOTHEKER ZEITUNG, Dt. Apotheker-Verlag, DE, DE , (20130314), vol. 153, no. 11, ISSN 0011-9857, pages 40 (1048) - 41 (1049), XP009554480-
OPPOSITION- Karl Mann, "Extending the Treatment Options in Alcohol Dependence: A Randomized Controlled Study of As-Needed Nalmefene", Biological Psychiatry, ELSEVIER, AMSTERDAM, NL, AMSTERDAM, NL, (20130401), vol. 73, no. 8, doi:10.1016/j.biopsych.2012.10.020, ISSN 0006-3223, pages 706 - 713, XP093168673
OPPOSITION- B Rounsaville, "Single versus multiple drug focus in substance abuse clinical trials research", DRUG AND ALCOHOL DEPENDENCE, ELSEVIER SCIENTIFIC PUBLISHERS, IR, IR , (20030521), vol. 70, no. 2, doi:10.1016/S0376-8716(03)00033-4, ISSN 0376-8716, pages 117 - 125, XP093168666
OPPOSITION- K. Mann, "P-59 - Shifting the paradigm: reduction of alcohol consumption in alcohol dependent patients - a randomised, double-blind, placebo-controlled study of nalmefene, as-needed use", European Psychiatry, Editions scientifiques et medicales Elsevier, FR, FR , (20120101), vol. 27, no. Suppl. 1, doi:10.1016/S0924-9338(12)74226-8, ISSN 0924-9338, page 1, XP093168759
OPPOSITION- Anonymous, "Nalmefene reduces alcohol use in phase III trial", Nature Reviews Drug Discovery, Nature Publishing Group, GB, GB , (20110801), vol. 10, no. 8, doi:10.1038/nrd3518, ISSN 1474-1776, page 566, XP093168761
OPPOSITION- NEW & ANALYSYS, "Nalmefene reduces alcohol use in Phase III trial ", Nature Review Drug Discovery, (20110810), vol. 10, doi:10.1038/nrd3518, XP093168761
OPPOSITION- Aron N. Starosta, "The BRENDA Model: Integrating Psychosocial Treatment and Pharmacotherapy for the Treatment of Alcohol Use Disorders : ", Journal of Psychiatric Practice, (20060301), vol. 12, no. 2, doi:10.1097/00131746-200603000-00003, ISSN 1538-1145, pages 80 - 89, XP093168670
OPPOSITION- Niamh Fitzgerald; Kathryn Angus; Andrew Elders; Marisa Andrade; Duncan Raistrick; Nick Heather; Jim McCambridge, "Weak evidence on nalmefene creates dilemmas for clinicians and poses questions for regulators and researchers", ADDICTION, CARFAX, ABINGDON, GB, GB , (20160605), vol. 111, no. 8, doi:10.1111/add.13438, ISSN 0965-2140, pages 1477 - 1487, XP071914235
OPPOSITION- Sakari Karhuvaara, Kaarlo Simojoki, Antti Virta, Markus Rosberg, Eliisa Löyttyniemi, Tommi Nurminen, Antero Kallio, Rauno Mäkelä, "Targeted Nalmefene With Simple Medical Management in the Treatment of Heavy Drinkers: A Randomized Double-Blind Placebo-Controlled Multicenter Study", ALCOHOLISM: CLINICAL AND EXPERIMENTAL RESEARCH., Wiley-Blackwell Publishing, Inc., US, US , (20070701), vol. 31, no. 7, doi:10.1111/j.1530-0277.2007.00401.x, ISSN 0145-6008, pages 1179 - 1187, XP055072462
OPPOSITION- K. Humphreys, "Use of Exclusion Criteria in Selecting Research Subjects and Its Effect on the Generalizability of Alcohol Treatment Outcome Studies", AMERICAN JOURNAL OF PSYCHIATRY., American Psychiatric Publishing, Inc., US, US , (20000401), vol. 157, no. 4, doi:10.1176/appi.ajp.157.4.588, ISSN 0002-953X, pages 588 - 594, XP093168668
SEARCH- SINCLAIR JOHN DAVID, "Evidence about the use of naltrexone and for different ways of using it in the treatment of alcoholism", ALCOHOL AND ALCOHOLISM, PERGAMON, OXFORD, GB, (20010101), vol. 36, no. 1, doi:10.1093/ALCALC/36.1.2, ISSN 0735-0414, pages 2 - 10, XP002958401 [A] 1-13 * the whole document *
SEARCH- SAKARI KARHUVAARA ET AL, "Targeted Nalmefene With Simple Medical Management in the Treatment of Heavy Drinkers: A Randomized Double-Blind Placebo-Controlled Multicenter Study", ALCOHOLISM: CLINICAL AND EXPERIMENTAL RESEARCH., US, (20070419), vol. 31, no. 7, doi:10.1111/j.1530-0277.2007.00401.x, ISSN 0145-6008, pages 1179 - 1187, XP055072462 [A] 1-13 * the whole document *

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents